Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Summary

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.

Timeline

Start

2022-09-14

Primary completion

2029-09

Completion

2036-09

Drugs

Indications